These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2467958)

  • 41. Sensitivity of the Azure heparin assay and comparisons with activated clotting time and whole blood partial thromboplastin time.
    Salley SO; Whittlesey GC; Smith SM; Klein MD
    ASAIO Trans; 1990; 36(3):M687-91. PubMed ID: 2252784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS; Heinick J; Günzel P
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.
    Dehmer GJ; Lange RA; Tate DA; Pirwitz M; Daniel W; Fisher M; Bonnem EM
    Circulation; 1996 Nov; 94(9 Suppl):II347-52. PubMed ID: 8901773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.
    Hubbard AR; Jennings CA
    Thromb Haemost; 1985 Feb; 53(1):86-9. PubMed ID: 3158095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a new protamine titration method to assay heparin in whole blood and plasma.
    Schlueter AJ; Pennell BJ; Olson JD
    Am J Clin Pathol; 1997 May; 107(5):511-20. PubMed ID: 9128262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin assay and protamine titration.
    Anido G; Freeman DJ
    Am J Clin Pathol; 1981 Oct; 76(4):410-5. PubMed ID: 7293964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of two methods for heparin monitoring: a semi-automated heparin monitoring device and activated clotting time during extracorporeal circulation.
    Stead SW
    Int J Clin Monit Comput; 1989 Dec; 6(4):247-54. PubMed ID: 2628513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring heparin anticoagulation and its neutralization.
    Jobes DR; Schwartz AJ; Ellison N; Andrews R; Ruffini RA; Ruffini JJ
    Ann Thorac Surg; 1981 Feb; 31(2):161-6. PubMed ID: 6970019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does protamine chloride neutralize low molecular weight heparin sufficiently?
    Gram J; Mercker S; Bruhn HD
    Thromb Res; 1988 Dec; 52(5):353-9. PubMed ID: 2851882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved protamine-sensitive membrane electrode for monitoring heparin concentrations in whole blood via protamine titration.
    Ramamurthy N; Baliga N; Wahr JA; Schaller U; Yang VC; Meyerhoff ME
    Clin Chem; 1998 Mar; 44(3):606-13. PubMed ID: 9510869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polycations as possible substitutes for protamine in heparin neutralization.
    Fabian I; Aronson M
    Thromb Res; 1980 Jan 1-15; 17(1-2):239-47. PubMed ID: 7376131
    [No Abstract]   [Full Text] [Related]  

  • 55. Protamine--the need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass.
    Keeler JF; Shah MV; Hansbro SD
    Anaesthesia; 1991 Nov; 46(11):925-8. PubMed ID: 1750591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid Equilibrated Colorimetric Detection of Protamine and Heparin: Recognition at the Nanoscale Liquid-Liquid Interface.
    Chen Q; Li X; Wang R; Zeng F; Zhai J; Xie X
    Anal Chem; 2019 Aug; 91(16):10390-10394. PubMed ID: 31339689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversible sensing of the anticoagulant heparin with protamine permselective membranes.
    Crespo GA; Afshar MG; Bakker E
    Angew Chem Int Ed Engl; 2012 Dec; 51(50):12575-8. PubMed ID: 23124959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing heparin neutralization following cardiac surgery: sensitivity of thrombin time-based assays versus protamine titration methods.
    LaDuca FM; Zucker ML; Walker CE
    Perfusion; 1999 May; 14(3):181-7. PubMed ID: 10411247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay.
    Umlas J; Gauvin G; Taff R
    Ann Thorac Surg; 1984 Apr; 37(4):301-3. PubMed ID: 6712330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of the heparin neutralizing capacity of protamine.
    Graham DT; Pomeroy AR; Smythe DB
    Thromb Haemost; 1979 May; 41(3):583-9. PubMed ID: 462424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.